## Welcome to Gu Mi's Website

Thank you for visiting! This website serves as a repository of my research works. My published papers and the accompanying software can be downloaded here. Some ongoing works may also be available after a public presentation.

### Peer-Reviewed Publications

* **Mi, G**. (2017). [Enhancement of the Adaptive Signature Design for Learning and Confirming in a Single Pivotal Trial](http://onlinelibrary.wiley.com/doi/10.1002/pst.1811/full). Pharmaceutical Statistics.
* **Mi, G.**, & Di, Y. (2015). [The Level of Residual Dispersion Variation and the Power of Differential Expression Tests for RNA-Seq Data](http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0120117). PLOS ONE, 10(4), e0120117.
* **Mi, G.**, Di, Y., & Schafer, D. W. (2015). [Goodness-of-fit tests and model diagnostics for negative binomial regression of RNA sequencing data](http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0119254). PLOS ONE, 10(3), e0119254.
* **Mi, G.**, Di, Y., Emerson, S., Cumbie, J. S., & Chang, J. H. (2012). [Length bias correction in gene ontology enrichment analysis using logistic regression](http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0046128). PLOS ONE, 7(10), e46128.
* Di, Y., **Mi, G.**, Sun, L., Dong, R., Zhu, H., & Peng, L. (2011, November). [Power of association tests in the presence of multiple causal variants](http://bmcproc.biomedcentral.com/articles/10.1186/1753-6561-5-S9-S63). In BMC proceedings (Vol. 5, No. 9, p. 1). BioMed Central.

### Conference Presentations

#### Statistical Conferences

* **Mi G**. "Enhancement of the Adaptive Signature Design for Learning and Confirming in a Single Pivotal Trial". Oral Presentation at 2017 ICSA Applied Statistics Symposium.
* **Mi G**, Nguyen T, and Denne J. "Subgroup Determination by Cross-Validation in STEPP". Oral Presentation at JSM 2016.
* **Mi G**. "Cross-Validated STEPP Analysis for Biomarker Subgroup Determination Problems". Oral Presentation at the 39th Midwest Biopharmaceutical Statistics Workshop (2016).
* **Mi G** and Di Y. "Power-Robustness Analysis of Statistical Models for RNA-Seq Data". Oral presentation at 2014 ICSA Joint Applied Statistics Symposium.
* **Mi G**, Zheng J and Farmen M. "Comparing Methods for Detecting Differential Exon Usage and Splicing from RNA-Seq Data". Poster presentation at 2013 Summer intern at Eli Lilly & Co. Also presented in 2013 CGRB Fall Conference and Statistics 2013 Oregon.
* **Mi G**, Di Y, Schafer D and Chang JH. "Goodness-of-Fit Tests and Diagnostics for Negative Binomial Regression of RNA-Seq Data". Oral presentation at JSM 2013.
* Di Y, **Mi G**, Emerson S and Schafer D. "Assessing Models of RNA-Sequencing Data". Poster presentation at JSM 2013.

#### Medical Conferences

* Arkenau, HT, Bendell, J, Herbst, R, **Mi, G**, et al. Ramucirumab plus pembrolizumab in previously treated advanced or metastatic biliary tract cancer: A multi-disease phase 1 study. Annals of Oncology. 2017 Jun 1; 28(suppl_3).
* Golan, T, Lin, CC, Fu, S, Wasserstrom, H, **Mi, G**, et al. A multi-cohort phase 1 study of ramucirumab plus durvalumab: Preliminary safety and clinical activity in patients with locally advanced and unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. Annals of Oncology. 2017 Jun 1; 28(suppl_3).
* Chau, I, Bendell, JC, Calvo, E, Santana-Davila, R, Arkenau, HT, **Mi, G**, et al. Ramucirumab (R) plus pembrolizumab (P) in treatment naive and previously treated advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: A multi-disease phase I study. Journal of Clinical Oncology 35, no. 15_suppl (May 2017) 4046-4046.
* Herbst, RS, Martin-Liberal, J, Calvo, E, Isambert, N, Bendell, J, Cassier, P, Jin, J, **Mi, G**, et al. Previously treated advanced NSCLC cohort from a multi-disease phase 1 study of ramucirumab (R) plus pembrolizumab (P): Efficacy and safety data. Annals of Oncology. 2017 Apr 1;28(suppl_2).
* Genova, C, Varella-Garcia, M, Rivard, C, Socinski, M, Hozak, R, **Mi, G**, et al. "EGFR FISH as Potential Predictor of Necitumumab Benefit with Chemotherapy in Squamous NSCLC: Subgroup Analyses from SQUIRE". Journal of Thoracic Oncology, 12(1), pp.S955-S956 (2017).
* Reck, M, Bang, YJ, Goff, L, Wasserstrom, H, Yang, J, **Mi, G** and Karasarides, M. "Multizentrische, offene Phase 1 Studie mit Ramucirumab plus Durvalumab bei Patienten mit inoperablem lokal fortgeschrittenen oder metastasierten Adenokarzinom des Magens oder gastrooesophagealen Übergangs (G/GEJ), nichtkleinzelligem Lungenkarzinom (NCSLC) oder hepatozellulärem Karzinom (HCC)". Pneumologie, 71(S 01), p.P5.
* Chau I, Bendell J, Calvo E, Santana-Davila R, Rodon J, Penel N, Arkenau HT, Yang J, Rege J, **Mi G**, et al. "Interim safety and clinical activity in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma from a multicohort phase 1 study of ramucirumab (R) plus pembrolizumab (P)". Poster at 2017 Gastrointestinal Cancers Symposium (ASCO GI).
* Petrylak DP, Arkenau H, Perez-Gracia JL, Krebs M, Santana-Davila R, Yang J, Rege J, **Mi G**, et al. "A multicohort phase 1 study of ramucirumab (R) plus pembrolizumab (P): interim safety and clinical activity in patients with urothelial carcinoma". Abstract at 2017 Genitourinary Cancers Symposium (ASCO GU).
* Lin CC, Golan T, Corral J, Moreno V, Chung HC, Wasserstrom H, Yang J, **Mi G**, et al. "Phase 1 study of ramucirumab (R) plus durvalumab (D) in patients (pts) with locally advanced and unresectable or metastatic gastrointestinal or thoracic malignancies (NCT02572687); phase 1a results". Proffered paper session at 2016 ESMO Symposium on Immuno-Oncology.
* Bang YJ, Goff LW, Wasserstrom H, Yang J, **Mi G**, et al. "An open-label, multicenter, phase 1 study of ramucirumab (R) plus durvalumab (D) in patients (pts) with locally advanced and unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), or hepatocellular carcinoma (HCC)". Trial in Progress at 2016 ESMO Symposium on Immuno-Oncology.
* Herbst R, Martin-Liberal J, Calvo E, Isambert N, Bendell J, Cassier J, Perez-Gracia JL, Yang J, Rege J, **Mi G**, et al. "Interim safety and clinical activity in patients with advanced NSCLC from a multi-cohort phase 1 study of ramucirumab (R) plus pembrolizumab (P)". Late-Breaking Poster Session at 2016 ESMO Congress.
* Herbst R, Bendell J, Isambert N, Calvo E, Santana-Davila R, Cassier P, Perez-Gracia JL, Yang J, Rege J, Ferry D, **Mi G**, and Chau I. "A phase 1 study of ramucirumab (R) plus pembrolizumab (P) in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), or urothelial carcinoma (UC): Phase 1a results" Postes at 2016 ASCO Annual Meeting.
* Rivard C, Boyle T, Ren Q, Kowalewski A, Hozak R,  **Mi G**, et al. "Mutation Prevalence for Oncogenic Drivers in Lung Adenocarcinoma". Mini Oral Presentation at the 16th World Conference on Lung Cancer (2015).
* Hirsch F, Boyle T, Thatcher N, Paz-Ares L, Varella-Garcia M, Kowalewski A, Hozak R, **Mi G**, et al. "EGFR IHC and FISH Correlative Analyses (SQUIRE Trial): Necitumumab + Gemcitabine-Cisplatin vs Gemcitabine-Cisplatin in 1st-Line Squamous NSCLC". Oral Presentation at the 16th World Conference on Lung Cancer (2015).

### Expert Reviewer

* *BMC Bioinformatics*
* *BMC Genomics*
* *Contemporary Clinical Trials*
* *Contemporary Clinical Trials Communications*
* *Journal of Biopharmaceutical Statistics*
* *Journal of Statistical Computation and Simulation*
* *PLOS ONE*
* *Research and Reports in Biology*
* *Advances in Obesity, Weight Management & Control*
